The reality of Ebola is simultaneously less sensational and far more challenging than most people imagine,” writes Krutika ...

The Supreme Court sided with the maker of Roundup weedkiller in a ruling expected to block thousands of lawsuits alleging it ...

A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central ...

You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence ...

WASHINGTON — Democratic lawmakers have questions about the 79-year-old patient who received special access in April to ...

At BIO 2026, executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug ...

John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — The chair of the ...

Chelsea covers the Department of Health and Human Services with a particular focus on power and influence at the top. Confidential tips can be sent via Signal at chelseacirruzzo.42. WASHINGTON — ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Megan covers the intersection of ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag of clinical AI, digital health at the FDA, and the boom in direct-to-consumer ...

What if you could precisely change the genome of a pre-implantation human embryo and then safely use that embryo to try to ...